Tissue Regenix Group PLC (AIM:TRX), the regenerative medicine specialist, has strategically positioned itself to capture a segment of the US sports medicine allograft tissue market, currently estimated at $300 million.
In an interview with Proactive, Daniel Lee and David Cocke, respectively CEO and CFO, discuss the opportunity alongside commentary on the firm's interims.
Bio Rinse minimises the effects of processing on the tissue, and so could potentially expedite recovery times for athletes — a factor that might give Tissue Regenix a competitive edge in this lucrative market.
As the sports medicine sector continues to grapple with the challenges of treating injuries like ACL tears and rotator cuff repairs, innovations such as Bio Rinse could play a more important role.